HTR1F 5-hydroxytryptamine receptor 1F
ENSG00000179097 · protein coding · Open Targets profile
G protein-coupled receptor for 5-hydroxytryptamine (serotonin) (PubMed:21422162, PubMed:34239069, PubMed:8380639, PubMed:8384716). Also functions as a receptor for various alkaloids and psychoactive substances (PubMed:21422162, PubMed:8380639, PubMed:8384716). Receptor for lasmiditan, a drug for the treatment of acute migraine (PubMed:34239069). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase (PubMed:34239069). HTR1F is coupled to G(i)/G(o) G alpha proteins and mediates inhibitory neurotransmission by inhibiting adenylate cyclase activity (PubMed:34239069, PubMed:35610220). {ECO:0000269|PubMed:21422162, ECO:0000269|PubMed:34239069, ECO:0000269|PubMed:35610220, ECO:0000269|PubMed:8380639, ECO:0000269|PubMed:8384716}.
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Approved Drug, Structure with Ligand, High-Quality Ligand, Druggable Family
- Antibody
- UniProt loc high conf, GO CC high conf, UniProt SigP or TMHMM
- PROTAC
- Small Molecule Binder
gnomAD loss of function constraint: o/e 0.7074400186538696 (upper bound 1.0611000061035156). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 26 registry trials, updated in the last three years, of the most advanced drugs against HTR1F (lasmiditan, eletriptan hydrobromide, amisulpride, almotriptan, eletriptan), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Angela M SousaUniversity of Sao Paulo · 1 of 1 trials Phase 2+
- Benedicto Crespo FacorroAndalusian Health Service · 1 of 1 trials Phase 2+
- Biswa R MishraAll India Institute of Medical Sciences, Bhubaneswar · 1 of 1 trials Phase 2+
- DengTang LiuShanghai Mental Health Center · 1 of 1 trials Phase 2+
- F. Markus LewekeCentral Institute of Mental Health · 1 of 1 trials Phase 2+
- Justin S LibermanVirginia Mason Medical Center · 1 of 1 trials Phase 2+
- Kumar BelaniUniversity of Minnesota Masonic Children's Hospital · 1 of 1 trials Phase 2+
- Christian KeicherCharite University, Berlin, Germany · 0 of 1 trials Phase 2+
- Diego PizzagalliMclean Hospital · 0 of 1 trials Phase 2+
- Gang ChenSir Run Run Shaw Hospital · 0 of 1 trials Phase 2+
- Guido FrankUniversity of California, San Diego · 0 of 1 trials Phase 2+
- Jijun WangShanghai Mental Health Center · 0 of 1 trials Phase 2+
- Licia GrazziFondazione IRCCS Istituto Neurologico Carlo Besta · 0 of 1 trials Phase 2+
- Stefan LeuchtPsychiatrische Klinik und Poliklinik fuer Psychiatrie und Psychotherapie der Technischen Universität München am Klinikum rechts der Isar · 0 of 1 trials Phase 2+
- Wenbin GuoThe Second Xiangya Hospital, Central South University · 0 of 1 trials Phase 2+
Registry trials of lasmiditan, eletriptan hydrobromide, amisulpride, almotriptan, eletriptan updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 21 of 24 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 2 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
10 trials of drugs against HTR1F were stopped early; 3 give no reason
Terminated, withdrawn and suspended interventional trials of lasmiditan, eletriptan hydrobromide, amisulpride, almotriptan, eletriptan, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 10 most recent of 10.
- terminated · 2026-09-02 · Eli Lilly and Company · Lasmiditan“Study terminated due to strategic business decision”
- terminated · 2026-06-25 · Eli Lilly and Company · Lasmiditan“Study terminated due to strategic business decision”
- terminated · 2025-05-31 · Messoud Ashina, MD · Almotriptan 12.5 Mg Oral Tablet“Issues with recruitment”
- withdrawn · 2024-06-24 · University of California, Los Angeles · Amisulpride 50 MG“Action of PI. Loss of sponsor”
- terminated · 2020-11-25 · RWTH Aachen University · matched by the registry's drug synonyms“slow patient recruitment, low patient-commpliance, high dropout rates,”
- terminated · 2018-02-28 · Hannover Medical School · AmisulprideNo reason given
- terminated · 2017-04-19 · Institute of Psychiatry, London · matched by the registry's drug synonyms“Failure to recruit people with very late onset schizophrenia like psychosis”
- terminated · 2016-03-01 · Kaohsiung Kai-Suan Psychiatric Hospital · full-dose amisulprideNo reason given
- withdrawn · 2015-12-09 · Geha Mental Health Center · Amisulpride, Clozapine+AmisulprideNo reason given
- terminated · 2008-09-16 · University of Jena · Amisulpride“Recruitment issues”
Paediatric incentives and obligations for HTR1F's drugs
For lasmiditan, eletriptan hydrobromide, amisulpride, almotriptan, eletriptan: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · HTR1F is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: yes · EMEA-002166-PIP01-17-M08 (lasmiditan, Treatment of migraine): PM: decision on the application for modification of an agreed PIP, 13 Sept 2024Rule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA EMEA-002166-PIP01-17-M08, 2026-11-11
- EU orphan designation: no · No EU orphan designation names lasmiditan, eletriptan hydrobromide, amisulpride, almotriptan, eletriptanRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: yes · Rayvow: authorised since 17 Aug 2022Rule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA EPAR Rayvow, 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of lasmiditan, eletriptan hydrobromide, amisulpride, almotriptan, eletriptanRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-12
- Registered studies open to children: yes · 12 interventional studies of lasmiditan, eletriptan hydrobromide, amisulpride, almotriptan, eletriptan include patients under 18; 0 are recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-12
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 11 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.